3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
19
Lymphoma, Mantle-Cell
9
Lymphoma, Non-Hodgkin
4
Multiple Myeloma
3
Lymphoma, Large B-Cell, Diffuse
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Pancreatic Neoplasms
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Squamous Cell Carcinoma of Head and Neck
1
Pyloric Stenosis, Hypertrophic
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Lymphoma, B-Cell
1
Leukemia, Prolymphocytic
1
Leukemia, Hairy Cell
1
Leukemia
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Glioblastoma
1
DLBCL
1
Chromosome 17 deletion
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Anemia, Hemolytic, Autoimmune
1
Advanced Haematological Malignancies
1
Interventions
BNT162 Vaccine
2
2019-nCoV Vaccine mRNA-1273
2
tocilizumab
1
sotrovimab
1
proxalutamide
1
bemcentinib
1
Therapeutics
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Sodium Chloride
1
Radiotherapy
1
Patient Reported Outcome Measures
1
Janus Kinase Inhibitors
1
Influenza Vaccines
1
Hydroxychloroquine
1
HuMax-IL8
1
Gelsolin
1
Diagnostic Tests, Routine
1
Decision Support Techniques
1
COVID-19 Vaccines
1
Blood Specimen Collection
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
COVID-19
×
acalabrutinib
×
Clear all
No trials found.